The importance of distinguishing "clinical judgement" in cancer management from "selection bias" in clinical trials.
作者信息
Markman M
出版信息
J Cancer Res Clin Oncol. 1996;122(10):573-4. doi: 10.1007/BF01221187.
Abstract
摘要
相似文献
1
The importance of distinguishing "clinical judgement" in cancer management from "selection bias" in clinical trials.区分癌症治疗中的“临床判断”与临床试验中的“选择偏倚”的重要性。
J Cancer Res Clin Oncol. 1996;122(10):573-4. doi: 10.1007/BF01221187.
2
Health services research in colorectal cancer: a quasi-experimental interventional pilot study on in- and outpatient oncology.结直肠癌的卫生服务研究：一项关于门诊和住院肿瘤学的准实验性干预性试点研究。
J Cancer Res Clin Oncol. 2021 Jun;147(6):1789-1802. doi: 10.1007/s00432-020-03454-w. Epub 2020 Dec 29.
3
Designs of preoperative biomarkers trials in oncology: a systematic review of the literature.肿瘤学术前生物标志物试验设计：文献系统综述。
Ann Oncol. 2015 Dec;26(12):2419-28. doi: 10.1093/annonc/mdv378. Epub 2015 Sep 14.
4
Critical evaluation of oncology clinical practice guidelines.肿瘤临床实践指南的批判性评价。
J Clin Oncol. 2013 Jul 10;31(20):2563-8. doi: 10.1200/JCO.2012.46.8371. Epub 2013 Jun 10.
5
Audit and feedback: effects on professional practice and healthcare outcomes.审核与反馈：对专业实践和医疗结果的影响。
Cochrane Database Syst Rev. 2012 Jun 13;2012(6):CD000259. doi: 10.1002/14651858.CD000259.pub3.
6
Putting Exercise Into Oncology Practice: State-of-the-Science, Innovation, and Future Directions.将运动融入肿瘤学实践：现状、创新和未来方向。
Cancer J. 2019 Sep/Oct;25(5):316-319. doi: 10.1097/PPO.0000000000000397.
7
The scientific bases of cancer management: at the interface between fundamental research and clinical practice.癌症管理的科学基础：基础研究与临床实践的交汇点。
J Cancer Res Clin Oncol. 1991;117(4):275-89. doi: 10.1007/BF01630709.
8
Randomisation to protect against selection bias in healthcare trials.随机化以防止医疗保健试验中的选择偏倚。
Cochrane Database Syst Rev. 2007 Apr 18(2):MR000012. doi: 10.1002/14651858.MR000012.pub2.
9
Reply to D. Milne et al.对D. 米尔恩等人的回复
J Clin Oncol. 2013 Jun 1;31(16):2055-6. doi: 10.1200/JCO.2013.49.1894.
10
[Standards, Options: Recommendations for the management of patients with epithelial ovarian cancer. Medical front-line treatment (summary report, update 2008)].
Gynecol Obstet Fertil. 2008 Jun;36(6):684-700. doi: 10.1016/j.gyobfe.2008.04.009. Epub 2008 Jun 9.
引用本文的文献
1
2
Use of progression-free survival as a valid endpoint in phase II cancer clinical trials.无进展生存期在癌症II期临床试验中作为有效终点的应用。
Curr Oncol Rep. 2007 May;9(3):159-60. doi: 10.1007/s11912-007-0015-2.
本文引用的文献
1
Paclitaxel (taxol).紫杉醇（泰素）。
N Engl J Med. 1995 Apr 13;332(15):1004-14. doi: 10.1056/NEJM199504133321507.
2
Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.紫杉醇用于转移性乳腺癌：一项针对蒽环类药物先前治疗后疾病复发患者进行的两剂量3小时输注试验。
J Natl Cancer Inst. 1995 Aug 2;87(15):1169-75. doi: 10.1093/jnci/87.15.1169.
3
Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.以3小时输注紫杉醇作为转移性乳腺癌初始及挽救性化疗的II期试验。
J Clin Oncol. 1995 Oct;13(10):2575-81. doi: 10.1200/JCO.1995.13.10.2575.
4
Evaluation of patients with advanced cancer using the Karnofsky performance status.使用卡诺夫斯基功能状态评分法对晚期癌症患者进行评估。
Cancer. 1980 Apr 15;45(8):2220-4. doi: 10.1002/1097-0142(19800415)45:8<2220::aid-cncr2820450835>3.0.co;2-q.
5
Importance of prognostic factors in cancer clinical trials.
Cancer Treat Rep. 1984 Jan;68(1):185-92.
6
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.
J Natl Cancer Inst. 1991 Dec 18;83(24):1797-805. doi: 10.1093/jnci/83.24.1797-a.
7
High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer.大剂量化疗联合自体骨髓移植治疗转移性乳腺癌。
J Clin Oncol. 1992 Apr;10(4):657-70. doi: 10.1200/JCO.1992.10.4.657.
Zotero 插件